Spring Bank Pharmaceuticals Nasdaq Listed Banner

News Release

Printer Friendly Version View printer-friendly version
<< Back
Spring Bank Pharmaceuticals to Present at the 19th Annual BIO CEO & Investor Conference in NYC

HOPKINTON, Mass., Feb. 06, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, cancer, and inflammatory diseases today announced that Martin Driscoll, President and Chief Executive Officer, will present at the 19th Annual BIO CEO & Investor Conference on Monday, February 13, 2017, at 5:00 p.m. Eastern Time in the Louis XVI presentation room. The conference is being held at the Waldorf Astoria Hotel in New York City.

Now in its 19th year, the BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies.

Management will be available to meet with investors throughout the day. Investors wishing to schedule a meeting should contact Spring Bank at jfreve@springbankpharm.com.

About Spring Bank Pharmaceuticals

Spring Bank Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using its proprietary small molecule nucleic acid hybrid, or SMNH, chemistry platform. SMNH compounds are small segments of nucleic acids that the company designs to selectively target and modulate the activity of specific proteins implicated in various disease states. The company is developing its most advanced SMNH product candidate, SB 9200, for the treatment of viral diseases, including hepatitis B virus. SB 9200 has been designed to selectively activate within infected cells the cellular proteins, retinoic acid-inducible gene 1, or RIG-I, and nucleotide-binding oligomerization domain-containing protein 2, or NOD2, which have been implicated in the body’s immune response to viral infections. Spring Bank believes that SB 9200 may play an important role in antiviral therapy by modulating the body’s immune response through its mechanisms of action to fight viral infections such as HBV. For more information please visit: www.springbankpharm.com.

Contact:

Jon Freve
Chief Financial Officer
Spring Bank Pharmaceuticals
(508) 473-5993
jfreve@springbankpharm.com

Primary Logo

Spring Bank Pharmaceuticals Inc.